Transfer Reagents 4: Retro-Diels–Alder Routes to 3,6-Di(2-pyridyl)pyridazinonorbornadiene, a Test Bed for the Relative Dienofugacity of Isobenzofuran, Isoindole, and Anthracene

Davor Margetić; Douglas N. Butler; Ronald N. Warrener

doi:10.1055/s-0033-1339879

Synlett, Table of Contents

Synlett 2013; 24(19): 2609-2613
DOI: 10.1055/s-0033-1339879

letter

Transfer Reagents 4: Retro-Diels–Alder Routes to 3,6-Di(2-pyridyl)pyridazinonorbornadiene, a Test Bed for the Relative Dienofugacity of Isobenzofuran, Isoindole, and Anthracene

Davor Margetić*

^aLaboratory for Physical-organic Chemistry, Division of Organic Chemistry and Biochemistry, Ruđer Bošković Institute, Bijenička c. 54, 10000 Zagreb, Croatia Fax: +385(1)4561008 Email: margetid@irb.hr

,

Douglas N. Butler

^bCentre for Molecular Architecture, Central Queensland University, Rockhampton, Queensland 4702, Australia

,

Ronald N. Warrener

^bCentre for Molecular Architecture, Central Queensland University, Rockhampton, Queensland 4702, Australia

› Author Affiliations

Abstract

All articles of this category

Abstract

Norbornadiene cycloadducts reacted with 3,6-di(2-pyridyl)-s-tetrazine to produce pyridazines (diene-protected alkenes), following dehydrogenation (by DDQ) of the intermediate dihydropyridazines. The title 3,6-di(2-pyridyl)-pyridazinonorbornadiene was produced under flash vacuum pyrolysis conditions by ejection of anthracene (590 °C), isobenzofuran (630 °C) or isoindole (580 °C) from the corresponding pyridazines, establishing the following dienofugacity order: isoindole > anthracene > isobenzofuran. Calculations of the respective retro-Diels–alder activation energies at the B3LYP/6-31G* level of theory correctly predicted the experimentally found isobenzofuran > anthracene > isoindole order. Cavity bis-3,6-di(2-pyridyl)-pyridazine (dppn) and chevron-shaped bis-dppn ligands were prepared from the title compound by coupling at the norbornene π-bond.

Key words

cycloadditions - heterocycles - ligands - flash pyrolysis - alkenes

Full Text

References

References and Notes

1a Wang WJ, Wang SS. Synth. Methods 1993; 56: 1950
1b De Munno G, Bruno G. Acta Crystallogr., Sect. C: Cryst. Struct. Commun. 1984; 40: 2022

2a Atfah A, Tuhl AH, Akasheh TS. Polyhedron 1991; 10: 1485
2b Golka A, Craig DC, Paddon-Row MN. Aust. J. Chem. 1994; 47: 101

3 Andrew JE, Blake AB, Fraser LR. J. Chem. Soc., Dalton Trans. 1975; 800
4 Andrew JE, Ball PW, Blake AB. J. Chem. Soc., Chem. Commun. 1969; 143
5 Wang J.-S, Sheu C.-F, Lee J.-S. Acta Crystallogr., Sect. C: Cryst. Struct. Commun. 1999; 55: 1806
6 Warrener RN, Elsey GM, Houghton MA. J. Chem. Soc., Chem. Commun. 1995; 1417
7 Miller GP, Tetreau MC, Olmstead MM, Lord PA, Blach AL. Chem. Commun. 2001; 1758
8 Warrener RN, Elsey GM, Danka IV, Butler DN, Pekos P, Kennard CH. L. Tetrahedron Lett. 1994; 35: 6745

9a Baxter PN. W, Lehn J.-M, Fischer J, Youinou M.-T. Angew. Chem., Int. Ed. Engl. 1994; 33: 2284
9b Bassani DM, Lehn J.-M, Baum G, Fenske D. Angew. Chem., Int. Ed. Engl. 1997; 36: 1845
9c Semenov A, Spatz JP, Moller M, Lehn J.-M, Sell B, Schubert D, Weidl CH, Schubert US. Angew. Chem. Int. Ed. 1999; 38: 2457
9d Baxter PN. W, Lehn J.-M, Baum G, Fenske D. Chem. Eur. J. 2000; 6: 4510

10 Thébault F, Blake AJ, Wilson C, Champness NR, Schröder M. New J. Chem. 2006; 30: 1498

11a Warrener RN, Butler DN, Margetić D, Pfeffer FM, Russell RA. Tetrahedron Lett. 2000; 41: 4671
11b Warrener RN, Butler DN, Russell RA. Synlett 1998; 566
11c Warrener RN, Schultz AC, Butler DN, Wang S, Mahadevan IB, Russell RA. Chem. Commun. 1997; 1023

12a Sauer J, Heinrichs G. Tetrahedron Lett. 1966; 7: 4979
12b Wilson WS, Warrener RN. J. Chem. Soc., Chem. Commun. 1972; 211

13a Warrener RN, Wang JM, Weerasuria KD. V, Russell RA. Tetrahedron Lett. 1990; 31: 7069
13b Warrener RN, Russell RA, Solomon R, Pitt IG. Tetrahedron Lett. 1987; 28: 6503
13c Butler DN, Officer DL, Pitt IG, Warrener RN, Russell RA. Tetrahedron Lett. 1987; 28: 6507

14 Butler DN, Barrette A, Snow RA. Synth. Commun. 1975; 5: 101
15 Margetić D, Butler DN, Warrener RN. Aust. J. Chem. 2000; 53: 959
16 Warrener RN, Margetić D, Sun G. Tetrahedron Lett. 2001; 42: 4263

17a Warrener RN, Margetić D, Russell RA. Synlett 1998; 585
17b Warrener RN, Margetić D, Amarasekara AS, Butler DN, Mahadevan IB, Russell RA. Org Lett. 1999; 1: 199

18 Warrener RN, Margetić D, Amarasekara AS, Russell RA. Org. Lett. 1999; 1: 203
19 The NMR spectra were recorded in CDCl₃ solutions containing TMS as internal standard on a Bruker AMX-300 or a Bruker Avance DPX-400 NMR spectrometer fitted with a gradient quattro nucleus probe. Melting points were determined using a Gallenkamp digital melting point apparatus and are uncorrected. The high-resolution mass spectra were recorded on a Micromass Platform II single quadrupole AutoSpec instrument (ESMS, electrospray mass spectrometry in CH₂Cl₂). Radial chromatography was carried out with a chromatotron, model No. 79245T, using 1 mm plates with silica gel 60F₂₅₄ as the stationary phase. FVP experiments were conducted under vacuum (0.001 mbar) in an 600 × 10 mm Pyrex tube packed with broken glass and heated by a horizontally mounted ‘Thermolyne’ model 21100 tube furnace. Products were collected at the end of the furnace on the cooler part of the tube. Volatile products were condensed in a liquid nitrogen trap. New compounds were isolated by radial chromatography and gave satisfactory spectroscopic and analytical data (accurate mass). Compound 9 was prepared by a previously published procedure¹⁴ by reaction of anthracene and norbornadiene. Compounds 10 and 11 were prepared by a procedure analogous for the benzo crown ether derivative of 10.^18,19 1α,2β,3β,6β,7β,8α-15-Oxatetracyclo[6.6.1.1^3,6.0^2,7.0^9,14]-hexadeca-4,9,11,13-tetraene (10) A solution of 1,4-dihydro-1,4-epoxynaphthalene (1.0 g, 6.94 mmol) and cyclopentadiene (2.00 g, 30.3 mmol) in CHCl₃ (5 mL) was heated at 70 °C for 14 h in a glass high-pressure vessel. The solvent was removed under vacuum, and cyclopentadiene excess was removed under high vacuum to afford 10 as a yellow-colored oil (1.30 g, 89.2%). ¹H NMR (300 MHz, CDCl₃): δ = 1.37 (d, J = 8.0 Hz, 1 H, CH₂), 1.54 (dt, J = 8.0, 1.8 Hz, 1 H, CH₂), 2.37 (t, J = 1.8 Hz, 2 H, H _endo ), 2.92 (q, J = 1.8 Hz, 1 H, H_bridgehead-C), 4.96 (s, 2 H, H_bridgehead-O), 6.13 (t, J = 1.5 Hz, 2 H, =CH), 7.09 (dd, J = 5.5, 3.1 Hz, 2 H, H_Ar), 7.17 (dd, J = 5.5, 3.1 Hz, 2 H, H_Ar). ¹³C NMR (75 MHz, CDCl₃): δ = 44.4 (C _endo ), 49.3 (C_bridgehead-C), 53.7 (CH₂), 80.2 (C_bridgehead-O), 119.0 (=CH), 126.7 (C_ArH), 134.7 (C_ArH), 148.7 (C_Arq). ESI-HRMS: m/z calcd for C₁₅H₁₄O₁ [M]⁺: 210.1045; found: 210.1046. 1α,2β,3β,6β,7β,8α-15-Azatetracyclo[6.6.1.1^3,6.0^2,7. 0^9,14]-hexadeca-4,9,11,13-tetraene (11) A solution of 1,4-dihydro-1,4-iminonaphthalene (2.0 g, 13.9 mmol) and freshly distilled cyclopentadiene (5.00 g, 75.6 mmol) in CHCl₃ (10 mL) was heated at 70 °C overnight in a glass high-pressure vessel. The solvent was removed under vacuum and cyclopentadiene excess under high vacuum to afford 11 as a black-colored oil (2.10 g, 72.3%). ¹H NMR (300 MHz, CDCl₃): δ = 1.40 (d, J = 8.0 Hz, 1 H, CH₂), 1.57 (d, J = 8.0 Hz, 1 H, CH₂), 2.37 (s, 2 H, H _endo ), 2.92 (s, 2 H, H_bridgehead-C), 3.68 (br s, 1 H, NH), 4.23 (s, 2 H, H_bridgehead-N), 6.25 (s, 2 H, =CH), 7.02–7.06 (m, 2 H, H_Ar), 7.13–7.16 (m, 2 H, H_Ar). ¹³C NMR (75 MHz, CDCl₃): δ = 43.0 (C _endo ), 49.1 (C_bridgehead-C), 55.1 (CH₂), 63.0 (C_bridgehead-N), 119.3 (=CH), 125.8 (C_ArH), 136.2 (C_ArH), 153.1 (C_Arq). ESI-HRMS: m/z calcd for C₁₅H₁₅N₁ [M]⁺: 209.1204; found: 209.1195. 5,8-Di(2-pyridyl)-6,7-diaza-1α,2β,3α,10α,11β,12α-octacyclo[10.6.6.1^3,10.0^2,11.0^4,9.0^13,18.0^19,24]pentacosa-4,6,8,13,15,17,19,21,23-nonaene (14) A solution of alkene 9 (300 mg, 1.11 mmol) in CHCl₃ (10 mL) was treated with s-tetrazine (260 mg, 1.11 mmol) and refluxed overnight. To this mixture, DDQ (480 mg, 2.11 mmol) was added and refluxed overnight. Insoluble material was removed by filtration, and the residual liquid was washed with 3 M NaOH (3×), then with H₂O, dried (MgSO₄), and the solvent was removed under vacuum to afford 14 as a brown-colored powder (303 mg, 58.8%, mp 270–272 °C). ¹H NMR (300 MHz, CDCl₃): δ = 0.23 (d, J = 10.7 Hz, 1 H, CH₂), 1.08 (d, J = 10.7 Hz, 1 H, CH₂), 2.26 (s, 2 H, H _endo ), 4.24 (s, 2 H, H_bridgehead-C), 4.46 (s, 2 H, H_{bridgehead-2.2.2}), 6.99–7.01 (m, 2 H, Ar), 7.19–7.22 (m, 2 H, H_Ar), 7.24–7.27 (m, 2 H, H_Ar), 7.34–7.39 (m, 4 H, H_Ar), 7.87 (dd, J = 6.4, 1.3 Hz, 2 H, H_Ar), 8.51 (dt, J = 7.1, 0.8 Hz, 2 H, H_Ar), 8.85 (d, J = 4.4 Hz, 2 H, H_Ar). ¹³C (NMR (75 MHz, CDCl₃): δ = 41.2 (CH₂), 46.1 (C_{bridgehead-norb}), 46.8 (C _endo ), 48.8 (C_{bridgehead-anthrac}), 123.3, 123.9, 124.0, 125.2, 126.0, 126.8, 137.1, 142.7 (C_Arq), 145.4 (C_Arq), 149.6, 151.1 (C_Arq), 151.8 (C_Arq), 156.2 (C_Arq). ESI-HRMS: m/z calcd for C₃₃H₂₄N₄ [M]⁺: 476.2001; found: 476.2001. 16,19-Di(2-pyridyl)-14-oxa-1β,2β,3α,10α,11β,12β-hexacyclo[10.6.1.1^3,10.0^2,11.0^4,9.0^15,20]icosa-4,6,8,15,17,19-hexaene (16) A solution of alkene 10 (430 mg, 2.05 mmol) in CHCl₃ (5 mL) was treated with s-tetrazine (483 mg, 2.05 mmol) and refluxed overnight. To this mixture, DDQ (900 mg, 4.0 mmol) was added and refluxed overnight. Insoluble material was removed by filtration, and the residual liquid was washed with 3 M NaOH (3×), then with H₂O, dried (MgSO₄), and the solvent was removed under vacuum to afford a brown-colored oil, which was subjected to radial chromatography (CHCl₃–MeOH = 10:1) to afford 16 as a colorless solid (331 mg, 38.8%, mp 202–205 °C). ¹H NMR (300 MHz, CDCl₃): δ = 1.81 (d, J = 9.3 Hz, 1 H, CH₂), 1.93 (d, J = 9.3 Hz, 1 H, CH₂), 2.86 (dd, J = 3.0, 1.6 Hz, 2 H, H _endo ), 4.63 (d, J = 1.1 Hz, 2 H, H_bridgehead-C), 5.10 (s, 2 H, H_bridgehead-O), 7.04–7.07 (m, 2 H, H_Ar), 7.14–7.17 (m, 2 H, H_Ar), 7.38–7.41 (m, 2 H, H_Ar), 7.90 (dt, J = 9.0, 1.8 Hz, 2 H, H_Ar), 8.69 (d, J = 8.0 Hz, 2 H, Ar), 8.84 (dd, J = 4.7, 0.6 Hz, 2 H, Ar). ¹³C NMR (75 MHz, CDCl₃): δ = 40.5, 50.1, 53.2 (CH₂), 79.6 (C_bridgehead-O), 119.5, 112.8, 120.1, 123.4, 126.6, 139.0, 149.3, 149.6, 150.1, 155.4, 160.1. ESI-HRMS: m/z calcd for C₂₇H₂₀N₄O₁ [M]⁺: 416.1637; found: 416.1638. 16,19-Di(2-pyridyl)-14-aza-1β,2β,3α,10α,11β,12β-hexacyclo[10.6.1.1^3,10.0^2,11.0^4,9.0^15,20]icosa-4,6,8,15,17,19-hexaene (18) A solution of alkene 11 (870 mg, 4.16 mmol) in CHCl₃ (5 mL) was treated with s-tetrazine (980 mg, 4.16 mmol) and refluxed overnight. To this mixture, DDQ (1.589 mg, 7.0 mmol) was added and refluxed overnight. Insoluble material was removed by filtration, and the residual liquid was washed with 3 M NaOH (3×), then with H₂O, dried (MgSO₄), and the solvent was removed under vacuum to afford a black-colored oily residue, which was subjected to radial chromatography (PE–EtOAc = 1:1, then the solvent polarity was gradually increased to EtOAc) to afford 18 as a black-colored solid (129 mg, 7.5%, mp 109–110 °C). ¹H NMR (300 MHz, CDCl₃): δ = 1.68 (br s, 1 H, NH), 1.80 (d, J = 9.2 Hz, 1 H, CH₂), 1.96 (d, J = 9.2 Hz, 1 H, CH₂), 2.69 (m, 2 H, H _endo ), 4.22 (s, 2 H, H_bridgehead-C), 4.64 (s, 2 H, H_bridgehead-N), 6.99–7.01 (m, 2 H, H_Ar), 7.11–7.13 (m, 2 H, H_Ar), 7.39–7.43 (m, 2 H, H_Ar), 7.88–7.93 (m, 2 H, H_Ar), 8.63–8.77 (m, 4 H, H_Ar). ¹³C NMR (75 MHz, CDCl₃): δ = 45.0 (C _endo ), 48.6 (C_bridgehead-C), 53.0 (CH₂), 61.8 (C_bridgehead-N), 119.5, 122.0, 123.8, 125.6, 137.0, 148.3, 149.4, 151.9, 152.9, 159.0. ESI-HRMS: m/z calcd for C₂₇H₂₁N₅ [M]⁺: 415.1797; found: 415.1794. 3,6-Di(2-pyridyl)-4,5-diaza-1α,8α-tricyclo[6.2.1.0^2,7]-undeca-2,4,6,9-tetraene (3) Compound 14 (50 mg 0.108 mmol) was subjected to FVP at 590 °C to give two fractions, one colorless solid (anthracene) and 3 as a brown-colored solid (14 mg, 43.5%). ¹H NMR (300 MHz, CDCl₃): δ = 2.36 (td, J = 7.9, 1.5 Hz, 1 H, CH₂), 2.41 (td, J = 7.9, 1.5 Hz, 1 H, CH₂), 5.16–5.18 (m, 2 H, H_bridgehead), 6.99 (t, J = 1.9 Hz, 2 H, =CH), 7.35 (dd, J = 6.3, 1.3 Hz, 1 H, H_Ar), 7.38 (dd, J = 6.3, 1.3 Hz, 1 H, H_Ar), 7.88, (td, J = 8.7, 1.8 Hz, 2 H, H_Ar), 8.56 (td, J = 8.0, 0.9 Hz, 2 H, H_Ar), 8.76–8.79 (m, 2 H, H_Ar). These values are consistent with those reported in the literature.¹⁴ 8,11-Di(2-pyridyl)-9,10-diazabicyclo[6.4.0]undeca-2,4,7,9,11-pentaene (8) Compound 24 (50 mg, 0.108 mmol) was subjected to FVP at 670 °C (in this experiment pyrolysis tube was not packed with broken glass) to give a black-colored oil, which was subjected to radial chromatography (CHCl₃–MeOH = 10:1) to afford 8 as a brown-colored oil (9 mg, 30.6%). ¹H NMR (300 MHz, CDCl₃): δ = 3.12 (d, J = 5.8 Hz, CH₂, 2 H), 6.10–6.18 (m, 1 H, =CH), 6.39 (dd, J = 7.9, 5.3 Hz, 1 H, =CH), 6.95 (dd, J = 10.5, 5.3 Hz, 1 H, =CH), 7.38–7.43 (m, 2 H, H_Ar), 7.72 (d, J = 11.6 Hz, 1 H, H_Ar), 7.86–7.91 (m, 2 H, H_Ar), 8.02 (d, J = 7.8 Hz, 1 H, =CH), 8.20 (d, J = 7.8 Hz, 1 H, H_Ar), 8.78 (d, J = 4.2 Hz, 2 H, H_Ar). ¹³C NMR (75 MHz, CDCl₃): δ = 30.0 (CH₂), 123.7, 125.1, 125.8, 127.3, 128.9, 126.1, 130.8, 132.7, 136.2, 137.6, 149.1, 149.2, 156.4, 156.8, 157.9. ESI-HRMS: m/z calcd for C₁₉H₁₂N₄ [M]⁺: 298.1218; found: 298.1198. 3,14,18,29-Tetra(carbomethoxy)-7,10,22,5-tetra(2-pyridyl)-32,34-dioxa-8,9,23,24-tetraaza-1α,2β,4β,5α,12α, 13β,15β,16α,17β,19β,20α,27α,28β,30β-dodecacyclo-[14.14.1.1^3,14.1^5,12.1^18,29.1^20,27.0^2,15.0^4,13.0^6,11.0^17,30.0^19,28.0^21,26]-pentatriaconta-6,8,10,21,23,25-hexaene (21) A solution of alkene 3 (100 mg, 0.336 mmol) and bisepoxide 20 (68 mg, 0.167 mmol) in THF (2 mL) was heated overnight at 140 °C in a sealed high-pressure glass vessel. The solvent was removed under vacuum, and the residue was subjected to radial chromatography (PE–EtOAc = 1:1, then the solvent polarity was gradually increased to EtOAc), to afford 21 as a brown-colored solid (128 mg, 76%, mp >350 °C). ¹H NMR (300 MHz, CDCl₃): δ = 1.34 (d, J = 9.1 Hz, 2 H, CH₂), 2.00 (s, 4 H, H _endo ), 2.04 (s, 2 H, CH₂), 2.22 (s, 2 H, H_bridgehead), 2.42 (s, 4 H, H _endo ), 2.82 (d, J = 9.1 Hz, 2 H, CH₂), 3.96 (s, 12 H, CO₂Me), 4.36 (s, 4 H, H_bridgehead-C), 7.39–7.41 (m, 4 H, H_Ar), 7.92 (dt, J = 6.1, 0.7 Hz, 4 H, H_Ar), 8.58 (d, J = 6.1 Hz, 4 H, H_Ar), 8.71 (d, J = 5.6 Hz, 4 H, H_Ar). ¹³C NMR (75 MHz, CDCl₃): δ = 28.7 (CH₂), 41.2, 42.3 (CH₂), 45.6, 52.6, 54.1, 56.6, 89.8 (C_bridgehead-O), 122.1, 123.3, 137.4, 149.3, 149.8, 152.3, 155.0, 169.2 (C=O). ESI-HRMS: m/z calcd for C₅₇H₄₈N₈O₁₀: 1004.3493 [M]⁺, 1027.3391 [M + Na]⁺, 1005.3557 [M + H]⁺; found: 1027.3352. 3,6,10,13-Tetra(2-pyridyl)-4,5,11,2-tetraaza-1α,8α-tetracyclo[6.6.1.0^2,7.0^9,14]pentadeca-2,4,6,9,11,13-hexaene (23) A solution of alkene 3 (55 mg, 0.125 mmol) in CHCl₃ (2 mL) was treated with s-tetrazine (30 mg, 0.125 mmol) and refluxed overnight. To this mixture, DDQ (227 mg, 1.0 mmol) was added and refluxed overnight. The insoluble material was removed by filtration, and the residual liquid was washed with 3 M NaOH (3×), then with H₂O, dried (MgSO₄), and the solvent was removed under vacuum. The residue was subjected to radial chromatography (PE–EtOAc = 1:1), to afford 23 as a brown-colored solid (21 mg, 22.5%, mp 302–304 °C). ¹H NMR (300 MHz, CDCl₃): δ = 2.99 (s, 2 H, H _endo ), 6.62 (s, 2 H, H_bridgehead), 7.30–7.34 (m, 4 H, H_Ar), 7.82 (dt, J = 6.1, 4.2 Hz, 4 H, H_Ar), 8.33–8.36 (m, 8 H, H_Ar). ¹³C NMR (75 MHz, CDCl₃): δ = 49.3 (C_bridgehead-C), 67.9 (CH₂), 123.4, 123.9, 137.0, 149.2, 151.5, 154.3, 155.7. ESI-HRMS: m/z calcd for C₃₁H₂₀N₈ [M]⁺: 504.1811; found: 504.1815.

Supplementary Material

Supporting Information